

South Carolina
Department of Health and Human Services
Post Office Box 8206
Columbia, South Carolina 29202-8206

Pharmacy and Therapeutics (P&T) Committee Meeting
August 1, 2012
MINUTES

1. Call to Order

A meeting of the P&T Committee convened at 4:00 p.m. on Wednesday, August 1, 2012.

2. Welcome

Deborah Tapley, R.Ph., called the meeting to order and welcomed members, guests, and staff members.

Ms. Tapley opened the meeting by stating that the P&T Committee meetings are held in compliance with the Freedom of Information Act's (FOIA) mandate that the public is notified when the public's business is being done, and that furthermore, the public has been notified that this facility is accessible to individuals with disabilities, and special accommodations could have been provided if requested in advance.

3. Committee Members Present:

Deborah Tapley, R.Ph.
Jony Bollinger, MD

Thomas Phillips, R.Ph.
Gregory Browning, MD

Kelly Jones, MD

SC DHHS Staff:

Vicki Johnson, J.D.
Valeria Williams

Magellan Medicaid Administration:

Mary Roberts, R.Ph.
Lisa Correll, PharmD

4. Discussion Topics

A. Committee Meeting Minutes, Wednesday, May 2, 2012.

The draft minutes from the previous P&T Committee meeting were emailed to the members so that they could review the document prior to the meeting. The minutes were approved unanimously.

B. Public Comment

Company	Speaker	Drug/Class
Johnson & Johnson	Janice M. Lopez, PharmD	Xarelto®
Merck & Co., Inc.	Vicki Star, MD	Juvisync™
AstraZeneca	Christy Cappelletti, PharmD	Symbicort®

C. Drug Classes for Review

Lisa Correll led the discussion for the following drug classes:

- Antidepressants, SSRIs
- Anticoagulants (Oral and Injectable)
- Topical Steroids (High Potency)
- Antihyperuricemics
- Hypoglycemics, Incretin Mimetics/Enhancers
- Glucocorticoids (Inhaled)

The chart below represents the recommendations from the P & T Committee:

ANTHYPERURICEMICS	
Preferred	Non-Preferred
Allopurinol	Uloric®
Colcrys®	Zyloprim®
Probenecid	
Probenecid/Colchicine	

ANTICOAGULANTS: ORAL	
Preferred	Non-Preferred
Pradaxa®	Coumadin®
Warfarin	Jantoven
Xarelto®	

ANTICOAGULANTS: INJECTABLE	
Preferred	Non-Preferred
Arixtra®	Lovenox®
Fragmin®	
Enoxaparin†	
†Status update that Enoxaparin will remain preferred.	

ANTIDEPRESSANTS, SSRIs	
Preferred	Non-Preferred
Citalopram	Fluoxetine 60mg
Fluoxetine (CAP/SOLN/TAB not DR)	Sertraline Concentrate
Fluvoxamine	
Paroxetine	
Sertraline	

GLUCOCORTICOIDS, INHALED	
Preferred	Non-Preferred
Advair Diskus®	
Advair HFA®	
Dulera®	
Symbicort®	

HYPOGLYCEMICS, INCRETIN MIMETICS/ENHANCERS	
Preferred	Non-Preferred
Janumet®	Juvisync™
Janumet XR®	
Januvia®	
Jentadueto®	
Kombiglyze XR®	
Onglyza®	
Tradjenta®	

TOPICAL STEROIDS, HIGH POTENCY	
Preferred	Non-Preferred
Beta-Val (Cream/Lotion)	Betamethasone Valerate (Oint)
Betameth Valerate (Cream/Lotion)	Betamet Diprop/Propyl Glycol (Lotion/Oint)
Betameth Diprop (Cream/Lotion)	Betamethasone Diprop (Gel/Oint)
Betameth/Dipro/Propyl Glycol (Cream)	Desoximetasone (Cream/Gel)
Fluocinonide (Cream/Emol/Gel/Soln)	Fluocinonide (Oint)
Triamcinolone Acetonide (Cream/Lotion/Oint)	

5. **Old Business**

Lisa Correll provided data requested by the P&T Committee during the May 2012 meeting.

6. **New Business**

7. **Resolved Items**

Recommendations regarding PDL status for drugs in the following classes were approved for submission to DHHS.

Antidepressants, SSRIs

Anticoagulants (Oral and Injectable)

Topical Steroids (High Potency)

Antihyperuricemics

Hypoglycemics, Incretin Mimetics/Enhancers

Glucocorticoids (Inhaled)

8. **Closing Comments**

The next meeting will be held on Wednesday, November 7, 2012, at 4:00 p.m.

9. **Adjournment**

The meeting adjourned at 5:25 p.m.